IP Library Granted Patent US 7,723,124
Granted Patent B2
US 7,723,124 · App. 11/052,748 · Granted May 25, 2010

Method for the rapid diagnosis of targets in human body fluids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,723,124
App. No.
11/052,748
Granted
May 25, 2010
Kind
B2
Abstract

More particularly, the present invention relates to a method for the detection of a target, e.g. pathogen in a human body fluid wherein a body fluid sample is collected with a swab member.

Claims (19)

1. A method for diagnosing conjunctivitis comprising the steps:

(a) non-invasively collecting a 0.1-100 μl eye fluid sample with a sterile swab member,

(b) directly contacting said swab member with a sample application zone without pretreatment of said sample on a sample analysis device wherein at least a part of said eye fluid sample is released directly into said sample application zone due to said swab member contacting said sample application zone,

(c) applying an elution medium to an absorbent pad on said sample analysis device to thereby transfer said sample to a detection zone comprising at least one immobilized binding partner, and

(d) analyzing the sample for the presence of at least one analyte related to conjunctivitis selected from the group consisting of at least one causative agent of conjunctivitis, at least one mediator of conjunctivitis, and both at least one causative agent of conjunctivitis and at least one mediator of conjunctivitis,

wherein said sample application zone and said detection zone are on a chromatographic test strip, and further comprising a conjugate zone between said absorbent pad and said sample application zone, wherein said conjugate zone comprises at least one labeled binding partner that is able to migrate with the elution medium.

2. The method of claim 1 wherein the sample is analyzed for the presence of a pathogen which is a causative agent of conjunctivitis or a plurality of such causative agents.

3. The method of claim 2 wherein the sample is analyzed for the presence of a pathogen selected from the group consisting of adenoviruses, herpes viruses, chlamydiae, cytomegaloviruses, amoebae and combinations thereof.

4. The method of claim 1 wherein the sample is analyzed for the presence of an allergy-associated component which is a causative agent or a mediator of conjunctivitis or a plurality of such causative agents and/or mediators.

5. The method of claim 1 wherein the sample is analyzed for the presence of a pathogen which is a causative agent of conjunctivitis or a plurality of such causative agents and at least one allergy-associated component which is a causative agent or a mediator of conjunctivitis or a plurality of such causative agents and/or mediators.

6. The method according to claim 1 , wherein said eye fluid sample is 0.2-20 μl.

7. The method according to claim 1 , wherein said eye fluid sample is 10-20 μl.

8. The method according to claim 1 , wherein said swab member comprises a polyester fleece sample collection material.

9. The method according to claim 1 , wherein said swab member directly contacts said sample application zone for less than or equal to twenty seconds.

10. The method according to claim 9 , wherein the swab member directly contacts said sample application zone for between 0.1 and 10 seconds.

11. The method of claim 1 , farther comprising the step of:

(e) determining at least one result of an analysis performed in step (d) within 20 minutes of collecting the sample in step (a).

12. The method of claim 11 , wherein the result is determined within 15 minutes of collecting the sample in step (a).

13. The method of claim 11 , wherein the result is determined within two to five minutes of applying the elution medium in step (c).

Assignments (10)
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: QUIDEL CORPORATION
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 068657/0827 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION
Reel/Frame 060220/0649 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2018
From: ROS ACQUISITION OFFSHORE LP
To: RAPID PATHOGEN SCREENING, INC.
Reel/Frame 047834/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2017
From: RAPID PATHOGEN SCREENING, INC.
To: QUIDEL CORPORATION
Reel/Frame 043926/0997 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CORPORATION
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044141/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2017
From: RAPID PATHOGEN SCREENING, INC.
To: QUIDEL CORPORATION
Reel/Frame 042829/0532 →
SECURITY INTEREST Recorded Oct 10, 2014
From: RAPID PATHOGEN SCREENING, INC.
To: ROS ACQUISITION OFFSHORE LP
Reel/Frame 033929/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2005
From: ABERL, FRANZ; SCHEIBENZUBER, MARCUS; SAMBURSKY, ROBERT P.; VANDINE, ROBERT W.; SAMBURSKY, JOSE S.
To: RAPID PATHOGEN SCREENING INC.
Reel/Frame 016259/0068 →